Quick Answer
LIPELLA PHARMACEUTICALS INC. reported Cash and Equivalents of $2.18 million for fiscal year 2024.
LIPELLA PHARMACEUTICALS INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $2.18M | -33.7% |
| 2023 | $3.29M | -35.7% |
| 2022 | $5.12M | +262.3% |
| 2021 | $1.41M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.86M | +37.1% | -33.3% |
| June 30, 2025 | $2.78M | +134.5% | -34.2% |
| March 31, 2025 | $4.23M | +100.7% | +93.4% |
| December 31, 2024 | $2.18M | -33.7% | +61.4% |
| September 30, 2024 | $1.35M | -43.8% | +14.1% |
| June 30, 2024 | $1.19M | -61.9% | -43.6% |
| March 31, 2024 | $2.11M | -47.6% | -36.1% |
| December 31, 2023 | $3.29M | -35.7% | +36.7% |
- LIPELLA PHARMACEUTICALS INC. showed a decrease of -33.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2024 period, LIPELLA PHARMACEUTICALS INC.’s cash and equivalents has grown by 54.5% (from $1.41 million to $2.18 million).
- The most recent figure is from LIPELLA PHARMACEUTICALS INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 28, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: